Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 17, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
- Transaction Price: $48.40 per American Depositary Receipt (ADR).
- Transaction Type: Increase in interest via dividend reinvestment.
- Dividend Payment Date: July 10, 2008.
Material Changes
The filing details specific increases in shareholdings for two individuals following the reinvestment of dividends:
- Mr. E J Gray: Increase of 12.58 ADRs.
- Mr. D J Phelan: Increase of 381.29 ADRs.
No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of ADRs held by Mr. E J Gray and Mr. D J Phelan post-transaction.
- Confirm the dividend amount per share that resulted in the reinvestment at $48.40 per ADR.
- Review the full SmithKline Beecham Mid-Term Incentive Plan terms to understand the scope of these transactions.